Fortress Biotech Inc

For the period ended Dec 31, 2023. Filed Mar 28, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 28, 2024

FBIO$1.99+7.6%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations


· · Year Ended December 31,
· 2023 · 2022
Revenue · ·
Product revenue, net	$59,662	$70,995
Collaboration revenue	5,229	1,882
Revenue - related party	103	192
Other revenue	19,519	2,674
Net revenue	84,513	75,743

Operating expenses
Cost of goods sold - product revenue	26,660	30,775
Research and development	101,747	134,199
Research and development - licenses acquired	4,324	677
Selling, general and administrative	94,124	113,656
Total operating expenses	226,855	279,307
Loss from operations	(142,342)	(203,564)

Other income (expense)
Interest income	3,003	1,398
Interest expense and financing fee	(15,315)	(13,642)
Change in fair value of warrant liabilities	4,424	1,129
Other income (expense)	(3,403)	1,215
Total other income (expense)	(11,291)	(9,900)
Loss before income tax expense	(153,633)	(213,464)

Income tax expense	521	449
Net loss	(154,154)	(213,913)

Net loss attributable to non-controlling interests	93,517	127,338
Net loss attributable to Fortress	(60,637)	$(86,575)

Preferred A dividends declared and paid	(8,032)	(8,032)
Net loss attributable to common stockholders	$(68,669)	(94,607)

Net loss per common share attributable to common stockholders - basic and diluted	$(8.47)	$(15.97)

Weighted average common shares outstanding - basic and diluted	8,110,906	5,924,967

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.